Literature DB >> 27863789

Comparative analysis of radioactive iodine versus thyroidectomy for definitive treatment of Graves disease.

Vincent T Wu1, Allison W Lorenzen1, Anna C Beck1, Vincent J Reid1, Sonia L Sugg1, James R Howe1, Janet H Pollard1, Geeta Lal1, Ronald J Weigel2.   

Abstract

BACKGROUND: Management of Graves disease includes antithyroid drugs, 131I therapy, or thyroidectomy. Our aim was to review our institutional experience with definitive treatments for Graves disease.
METHODS: This was a retrospective review of patients undergoing 131I therapy (n = 295) or thyroidectomy (n = 103) for Graves disease (2003-2015). Demographic, clinical, pathology, and outcome data were collected from institutional databases.
RESULTS: 131I therapy patients were older (39.1 years vs 33.4 years, P = .001). There was no difference in the presence of ophthalmopathy between groups. A larger proportion of children received thyroidectomy than 131I therapy (17.1% vs 9.2%, P = .026). The success rate of the first 131I therapy dose was 81.4%. Overall success rate, including additional doses, was 90.1%. Rapid turnover of iodine correlated with 131I therapy failure (58.3% rapid turnover failure vs 14.9% non-rapid turnover failure, P < .05). All surgical patients underwent total or near-total thyroidectomy. 131I therapy complications included worsening thyrotoxicosis (1%) and deteriorating orbitopathy (0.7%). Operative complications were higher than 131I therapy complications (P < .05) but were transient. There was no worsening orbitopathy or recurrent Graves disease among surgical patients.
CONCLUSION: A higher proportion of pediatric Graves disease patients underwent thyroidectomy than 131I therapy. Rapid turnover suggested more effective initial management with operation than 131I therapy. Although transient operative complications were high, 131I therapy complications included worsening of Graves orbitopathy among those with pre-existing orbitopathy.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27863789      PMCID: PMC5492886          DOI: 10.1016/j.surg.2016.06.066

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  23 in total

1.  Disparity in the management of Graves' disease observed at an urban county hospital: a decade-long experience.

Authors:  Judy Jin; Victor Sandoval; Mary E Lawless; Ashwini R Sehgal; Christopher R McHenry
Journal:  Am J Surg       Date:  2012-02-07       Impact factor: 2.565

Review 2.  Radioiodine therapy (RAI) for Graves' disease (GD) and the effect on ophthalmopathy: a systematic review.

Authors:  Shamasunder H Acharya; Alison Avenell; Sam Philip; Jennifer Burr; John S Bevan; Prakash Abraham
Journal:  Clin Endocrinol (Oxf)       Date:  2008-04-21       Impact factor: 3.478

Review 3.  Total thyroid ablation in Graves' orbitopathy.

Authors:  F Menconi; M Leo; P Vitti; C Marcocci; M Marinò
Journal:  J Endocrinol Invest       Date:  2015-03-05       Impact factor: 4.256

Review 4.  Comparative effectiveness of therapies for Graves' hyperthyroidism: a systematic review and network meta-analysis.

Authors:  Vishnu Sundaresh; Juan P Brito; Zhen Wang; Larry J Prokop; Marius N Stan; Mohammad H Murad; Rebecca S Bahn
Journal:  J Clin Endocrinol Metab       Date:  2013-07-03       Impact factor: 5.958

5.  Graves' disease: a long-term quality-of-life follow up of patients randomized to treatment with antithyroid drugs, radioiodine, or surgery.

Authors:  Mirna Abraham-Nordling; Ove Törring; Bertil Hamberger; Göran Lundell; Leif Tallstedt; Jan Calissendorff; Göran Wallin
Journal:  Thyroid       Date:  2005-11       Impact factor: 6.568

6.  Four- to twenty-four-hour uptake ratio: an index of rapid iodine-131 turnover in hyperthyroidism.

Authors:  R Aktay; K Rezai; J E Seabold; R S Bar; P T Kirchner
Journal:  J Nucl Med       Date:  1996-11       Impact factor: 10.057

7.  Surgical treatment of hyperthyroidism: a ten-year experience.

Authors:  P Werga-Kjellman; J Zedenius; L Tallstedt; F Träisk; G Lundell; G Wallin
Journal:  Thyroid       Date:  2001-02       Impact factor: 6.568

8.  Failure of radioactive iodine in the treatment of hyperthyroidism.

Authors:  David F Schneider; Philip E Sonderman; Michaela F Jones; Kristin A Ojomo; Herbert Chen; Juan C Jaume; Diane F Elson; Scott B Perlman; Rebecca S Sippel
Journal:  Ann Surg Oncol       Date:  2014-07-08       Impact factor: 5.344

9.  Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism. The Thyroid Study Group.

Authors:  L Tallstedt; G Lundell; O Tørring; G Wallin; J G Ljunggren; H Blomgren; A Taube
Journal:  N Engl J Med       Date:  1992-06-25       Impact factor: 91.245

10.  Clinical and socioeconomic factors influence treatment decisions in Graves' disease.

Authors:  Dawn M Elfenbein; David F Schneider; Jeffrey Havlena; Herbert Chen; Rebecca S Sippel
Journal:  Ann Surg Oncol       Date:  2014-09-23       Impact factor: 5.344

View more
  5 in total

1.  Transoral Vestibular Thyroidectomy: Current State of Affairs and Considerations for the Future.

Authors:  Jonathon O Russell; Christopher R Razavi; Mohammad Shaear; Lena W Chen; Andrew H Lee; Rohit Ranganath; Ralph P Tufano
Journal:  J Clin Endocrinol Metab       Date:  2019-03-12       Impact factor: 5.958

2.  Disease Burden and Outcome in Children and Young Adults With Concurrent Graves Disease and Differentiated Thyroid Carcinoma.

Authors:  Suzanne P MacFarland; Andrew J Bauer; N Scott Adzick; Lea F Surrey; Jessica Noyes; Ken Kazahaya; Sogol Mostoufi-Moab
Journal:  J Clin Endocrinol Metab       Date:  2018-08-01       Impact factor: 5.958

3.  The Efficacy and Short- and Long-Term Side Effects of Radioactive Iodine Treatment in Pediatric Graves' Disease: A Systematic Review.

Authors:  Sarah L Lutterman; Nitash Zwaveling-Soonawala; Hein J Verberne; Frederik A Verburg; A S Paul van Trotsenburg; Christiaan F Mooij
Journal:  Eur Thyroid J       Date:  2021-07-12

4.  Total thyroidectomy (Tx) versus thionamides (antithyroid drugs) in patients with moderate-to-severe Graves' ophthalmopathy - a 1-year follow-up: study protocol for a randomized controlled trial.

Authors:  Lindsay Brammen; Philipp Riss; Julius Lukas; Alois Gessl; Daniela Dunkler; Shuren Li; Asha Leisser; Sandra Rezar-Dreindl; Katharina Eibenberger; Andreas Selberherr; Christian Scheuba; Andrea Papp
Journal:  Trials       Date:  2018-09-15       Impact factor: 2.279

5.  Clinical Outcomes of Repeated Radioactive Iodine Therapy for Graves' Disease.

Authors:  Min Joo Kim; Sun Wook Cho; Ye An Kim; Hoon Sung Choi; Young Joo Park; Do Joon Park; Bo Youn Cho
Journal:  Endocrinol Metab (Seoul)       Date:  2022-06-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.